What is the current stock price of GT Biopharma, Inc. (GTBP)?

As of the latest market data, GT Biopharma, Inc. (GTBP) is trading at $0.37. The stock has seen a loss of -5.46% today.

Does GT Biopharma, Inc. (GTBP) pay a dividend?

Based on current data, GT Biopharma, Inc. does not have a confirmed active dividend policy.

What is the market cap of GT Biopharma, Inc.?

The current market capitalization of GT Biopharma, Inc. (GTBP) is approximately unavailable.

GTBP

GT Biopharma, Inc.·Healthcare

0.37

5.457%(−0.02)

Market Closed

0.43

15.176%(+0.06)

After Hours

Last Updated: — ET

52W L: $0.3652W H: $3.85

GTBP NEWS

defenseworld.net

Apr 2

Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)

Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Analyst Ratings This is a breakdown of recent

zacks.com

Mar 16

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com

Mar 12

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

globenewswire.com

Mar 11

GT Biopharma to Participate in the 38th Annual Roth Conference

SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will participate in the 38th Annual Roth Conference being held March 22-24, 2026 in Laguna Niguel, CA.

globenewswire.com

Mar 2

GT Biopharma Reports Full Year 2025 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5

globenewswire.com

Feb 17

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5th, 2026, in Toronto, Ontario.

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2018-03-27

Beta

1.20

Websitewww.gtbiopharma.com↗